ArticleBMC nephrology2026
Lipidomic profiling reveals medium-chain acylcarnitines alterations as metabolic signatures in IgA nephropathy.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide, exhibits highly variable clinical progression, ranging from asymptomatic urinary abnormalities with potential for spontaneous resolution to progressive kidney failure over 10–20 years. The limited understanding of IgAN pathogenesis continues to constrain the development of effective therapeutic strategies. To elucidate key pathogenic mechanisms, we performed both untargeted and quantitative lipidomic profiling in patients with IgAN. Our results revealed significant disruptions in carnitine metabolism, particularly involving medium-chain acylcarnitines. Notably, medium-chain acylcarnitine levels were strongly correlated with clinical markers of renal function, including serum creatinine and estimated glomerular filtration rate (eGFR). Given their role as key intermediates in mitochondrial fatty acid β-oxidation, we further investigated mitochondrial function. Analysis of transcriptomic data (GSE210098) showed that genes related to the mitochondrial respiratory electron transport chain and oxidative phosphorylation (OXPHOS) system were significantly downregulated in IgAN progressors. Moreover, OXPHOS activity was markedly impaired in renal tubular epithelial cells from IgAN patients (GSE171314). These findings implicate dysregulated medium-chain acylcarnitine metabolism as a potential contributor to IgAN pathogenesis. Importantly, our data suggest a protective role for carnitine in disease development, highlighting a potential novel therapeutic avenue for IgAN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.